GLUCOSE HEALTH, INC.

A Nevada Corporation

609 SW 8th Street
Suite 600
Bentonville, AR 72712

Telephone: (479) 802-3827
Corporate Website: www.glucosehealthinc.com

Federal EIN: 90-1117742
SIC Code: 2833

Quarterly Report/ Initial Disclosure Statement

For the period ending March 31, 2018
("the Reporting Period")

The number of shares outstanding of our Common Stock is 5,716,133 as of March 31, 2018
The number of shares outstanding of our Common Stock was 4,971,895 as of December 31, 2017 (end of previous reporting period)

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: ☐ No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

Indicate by check mark whether a change in control of the company has occurred over this reporting period:

Yes: ☐ No: ☒

We previously were a shell company, therefore the exemption offered pursuant to Rule 144 is not available. Anyone who purchased securities directly or indirectly from us or any of our affiliates in a transaction or chain of transactions not involving a public offering cannot sell such securities in an open market transaction.

TABLE OF CONTENTS

TABLE OF CONTENTS

CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS

Some of the statements in this report are "forward-looking statements." These forward-looking statements involve certain known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. The words "believe," "expect," "anticipate," "intend," "plan," and similar expressions identify forward-looking statements. We caution you not to place undue reliance on these forward-looking statements. We undertake no obligation to update and revise any forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements in this report to reflect any future or developments. However, the Private Securities Litigation Reform Act of 1995 is not available to us as a penny stock issuer and thus we may not rely on the statutory safe harbor from liability for forward-looking statements. Further, Section 27A(b)(2)(D) of the Securities Act of 1933 and Section 21E(b)(2)(D) of the Securities Exchange Act of 1934 expressly state that the safe harbor for forward looking statements does not apply to statements made in connection with any offering.

Part A General Company Information

Item 1: The name of the issuer and predecessors (if any).

Glucose Health, Inc. ("issuer," "Company," "we," "our," "us")

We were originally incorporated as Bio-Solutions, Inc. on March 7, 2007. We changed our name to Glucose Health, Inc. to reflect our current business on October 30, 2014. We have no parent, subsidiary or affiliated companies.

Item 2: The address of the issuer's principal executive offices.

The address of the issuer:	609 SW 8th Street Suite 600 Bentonville, AR 72712
The telephone and facsimile of the issuer:	Telephone: (479) 802-3827 Facsimile: (479) 802-3827
The issuer's website:	Corporate website: www.glucosehealthinc.com Consumer website: www.glucosehealth.com
The name and address of the issuer's transfer agent:	Nevada Agency and Transfer Company 50 West Liberty Street Reno Nevada, 89501

Item 3: The jurisdiction(s) and date of the issuer's incorporation or organization.

We were incorporated under the laws of the State of Nevada on March 27, 2007. Our corporate status is active.

Part B Share Structure

Item 4: The exact title and class of securities outstanding.

At March 31, 2018, Glucose Health, Inc. had two classes of securities outstanding; Common Stock and Series A Special Preferred Shares.

The CUSIP number for our Common Stock is 379894108.

The trading symbol assigned by FINRA for our Common Stock is "GLUC". Our securities are not, and have never been, listed on a national securities exchange and are quoted on OTC Link ATS.

Item 5: Par or stated value and description of the security.

Common Stock; $0.001 par value.

Holders of our Common Stock are entitled to receive such dividends and other distributions as may be authorized and declared by the Board of Directors from time to time. Upon the voluntary or involuntary liquidation, dissolution, or winding up of Glucose Health, Inc., holders of Common Stock are entitled to a *pro rata* share of the net assets available for distribution in proportion to the number of shares of Common Stock held by each stockholder.

We have never declared or paid a cash dividend. We do not expect to pay cash dividends in the foreseeable future. We currently intend to retain our earnings, if any, for use in our business. Any dividends declared in the future will be at the discretion of our board of directors and subject to any restrictions that may be imposed by our lenders.

Series A Special Preferred Shares; no par value.

Our Series A Special Preferred Shares consist of 1,000 shares of Series A Special Preferred Shares with special voting rights whereby the holder(s) may exercise their right to vote on all shareholder matters representing the number of votes equal to all shares of Common Stock then issued and outstanding, plus an additional ten thousand (10,000) shares.

Item 6: The number of shares or total amount of the securities outstanding for each class of securities authorized.

Common Stock; $0.001 par value.

As of March 31, 2018, there were 5,716,133 shares of Common Stock issued and outstanding with 4,721,334 held at DTCC (public float) and 200,000,000 shares of Common Stock authorized.

As of March 31, 2018, we had 120 shareholders of record. "Shareholders of record" do not include beneficial owners of our shares held in "street name" at brokerage and custodial firms, the accuracy of which cannot be guaranteed. We estimate our total number of shareholders, inclusive of shareholders of record and beneficial owners of our shares held in street name, to be greater than 1000.

Series A Special Preferred Shares; no par value.

As of March 31, 2018, there were 1,000 Series A Special Preferred Shares issued and outstanding and 1000 Series A Special Preferred Shares authorized.

Item 7: The name and address of the issuer's transfer agent*.

Our transfer agent is Nevada Agency & Transfer Company ("NATCO") located at 50 West Liberty Street, Reno, Nevada, 89501 with phone number is (775) 322-0626. NATCO is registered under the Securities Exchange Act of

1934 (the "Exchange Act") and regulated by the SEC. Glucose Health, Inc. is a participant in the OTCMarkets.com **Transfer Agent Verified Shares Program.**

Part C Business Information

Item 8: The nature of the issuer's business.

Business Development

Glucose Health, Inc. was incorporated under the laws of the State of Nevada on March 27, 2007. Our fiscal year end is December 31. We changed our name to Glucose Health, Inc. to reflect our current business on October 30, 2014. Our principal executive office is located at 609 SW 8th Street, Suite 600, Bentonville, AR 72712 and our telephone number is 479-802-3827. We utilize contract manufacturing facilities in Albert Lea, Minnesota and Gravette, Arkansas and a third-party logistics facility in Rogers, Arkansas. Our corporate website is www.glucosehealthinc.com, and our product website is www.glucosehealth.com. Our CUSIP number is 379894108 and our trading symbol is GLUC.

Changes in Control

On October 1, 2014, the Company entered into an Intellectual Property Purchase Agreement and issued 300,000 unregistered shares of the Company's Common Stock to corporation beneficially owned by the Company's CEO, Murray Fleming. Additionally, on October 1, 2014, the Company entered into an agreement and issued 300,000 unregistered shares of the Company's Common Stock to Mr. Fleming. The 300,000 shares issued to Mr. Fleming directly and the 300,000 shares issued to the corporation over which Mr. Fleming exercises voting control of the 300,000 shares, constitute a change of the control of the Company. At October 1, 2014, Mr. Fleming beneficially owned 600,000 shares or 50.1% of the outstanding shares of the Company's Common Stock.

Business of Issuer

We are a manufacturer of dietary supplements marketed under the Glucose Health® brand, which serve the over-the-counter, diabetic nutritionals, consumer market segment. Our Standard Industrial Classification (SIC) code is 2833 (Medicinal Chemicals and Botanical Products). Our predecessor, Bio-Solutions Inc., for a period of time in fiscal 2007, was a "shell" company. Glucose Health, Inc. is not a "shell" company. As discussed in greater detail below, we are in the early stages of developing, manufacturing, marketing and distributing our dietary supplement products. For the fiscal quarter ending March 31, 2018, we generated a gross profit of $14,864, a loss from operations of $8,111 and net loss of $12,009 or $0.00 per share.

Item 9: The nature of products or services offered.

Glucose Health, Inc. manufacturers and distributes dietary supplements under the Glucose Health® brand. Our dietary supplements are formulated with ingredients demonstrated in certain clinical research, such as published on the National Institutes of Health, National Library of Medicine website (see www.glucosehealth.com/clinical-trials), to have a beneficial impact upon blood glucose, triglyceride and cholesterol levels and digestive health. The Centers for Disease Control and Prevention (CDC) publishes a National Diabetes Statistics Report annually. The 2014 Report estimates 2 of 5 presently healthy Americans will develop Type-2 diabetes in their lifetime. We believe the CDC Report and other similar research points to a large and growing market of consumers likely concerned with pre-diabetes or Type-2 diabetes, including many of whom are also likely purchasers of dietary supplements. While our primary focus is growing our sales to these consumers through national and regional pharmacy chain retailers, secondarily, we also market Glucose Health® to these customers via selected online marketplaces.

On October 1, 2014, the Company entered into an agreement to acquire the "Glucose Health" intellectual property from a corporation beneficially owned by the Company's CEO.

Beginning in October 2014, we undertook a series of steps to achieve commercialization of a "Glucose Health" dietary supplement product that would be considered both efficacious and pleasant tasting by our target consumer market, being persons concerned with pre-diabetes and Type-2 diabetes; and further would offer a value proposition, relative to our competition, to be favorably considered by national and regional pharmacy chain retailer buyers for inclusion on their store shelves. This series of steps included retaining a former head of beverage product development at Nestle to refine our product formula; retaining an attorney specializing in Food and Drug Administration (FDA) and Federal Trade Commission (FTC) regulations pertaining to dietary supplements to establish and ensure our compliance with such regulations; conducting an international graphic design competition for branding Glucose Health; retaining an experienced graphic artist specializing in consumer product packaging to create all digital and print representations of Glucose Health; and filing and being granted trademark protection for Glucose Health® with the United States Trademark and Patent Office (USPTO).

On October 30, 2014, we changed our name from Bio-Solutions Inc. to Glucose Health, Inc. to reflect our current business.

On January 5, 2015, we signed a contract manufacturing agreement for testing, compounding, supply and order fulfillment for the first iteration of the Glucose Health® product and additionally a purchasing agreement to distribute the first iteration of the product through a limited number of Northwest Arkansas pharmacies.

On January 7, 2015, we completed implementation of Current Good Manufacturing Practices (CGMP). The Dietary Supplement (DS) CGMP rule in 21 CFR part 111 of the FDA's regulations requires companies which manufacture, package, label, or hold a dietary supplement to establish and follow current good manufacturing practice to ensure the quality of the dietary supplement and to ensure that the dietary supplement is packaged and labeled as specified in the master manufacturing record.

On January 26, 2015, we filed an initial application for trademark protection related to its line of dietary supplement products, with the United States Trademark and Patent Office (USPTO).

On January 29, 2015, we appointed Chandrasekhar Mallangi, Ph.D., as an advisor. Dr. Mallangi earned a Ph.D. in Food Science from Oregon State University and is an advisor to multinational companies in the development of nutritional products. Dr. Mallangi is the credited inventor and co-inventor for patents awarded by the USPTO to subsidiaries of Nestle, SA of Vevey, Switzerland.

On February 10, 2015, Murray Fleming, our Chief Executive Officer was appointed our Chief Financial Officer.

On February 24, 2015, we completed FDA facility registration, a compliance procedure for manufacturers of dietary supplements.

On May 26, 2015, we completed the first production run of the first iteration of Glucose Health and pursuant to the January 5, 2015 purchasing agreement, the first iteration of Glucose Health began to be offered for retail sale through a limited number of Northwest Arkansas pharmacies as well as on our product website www.glucosehealth.com.

On July 7, 2015, we received notification from the United States Patent and Trademark Office (USPTO) that its application for trademark of "Glucose Health" was accepted to the Supplemental Register (Reg. 4,770,720) with first use recognized by the USPTO as of February 1, 2015.

On January 6, 2016, we executed a supplier agreement with a large national pharmacy retailer.

On February 4, 2016, our Chief Executive Officer and Chief Financial Officer, Murray Fleming, was appointed to our board of directors.

On March 8, 2016, we received a series of material purchase orders from a large national pharmacy retailer pursuant to a material supplier agreement.

On October 4, 2016, we executed a non-recourse receivables financing agreement with Citibank, N.A. (Citibank) whereby receivables are paid to us by Citibank for a large pharmacy retailer customer, subject to an interest premium.

In April 2017, we undertook a series of steps to achieve production of a new and improved, second iteration, Glucose Health® dietary supplement product. This series of steps included improving the nutritional formula with the addition of 6 targeted vitamins and minerals and the natural plant extract Banaba Leaf; implementation of an additional manufacturing process to agglomerate the product formula to improve solubility; sourcing natural flavors from an industry leading flavoring house; and improving product directions and packaging information based upon consumer feedback from the first iteration product.

In February 2018, we introduced new Glucose Health® Diabetic-Friendly Iced Tea Mix in Mixed Berry, Triple Berry, Lemon and Peach flavors. We are engaged in active development of additional products targeting our market niche

As of March 31, 2018, Glucose Health® dietary supplements are stocked by pharmacy chain retailers in all 50 states and are additionally available for purchase in selected online marketplaces.

Competition

The business of developing and distributing dietary supplements is highly competitive. Our product has direct and indirect competition. We compete with Glucerna® Advance, manufactured by Abbott Laboratories; Boost® Glucose Control, manufactured by Nestle; and Enterex® Diabetic, manufactured by Victus, Inc. All the companies whom are our direct competitors are substantially larger with much greater financial resources and broader name recognition. Although we are a small company, we believe we have a competitive advantage over our larger competitors because our Glucose Health® products are specifically targeted and formulated for persons concerned with pre-diabetes, Type-2 diabetes and digestive health. For example, our Glucose Health® branded products include soluble fiber, plant-based extracts and various micronutrients; each of which have been demonstrated in certain clinical studies to have beneficial impacts levels with respect to blood glucose, triglycerides and cholesterol and digestive health. We also compete with Metamucil manufactured by Procter and Gamble and with the many dietary supplements marketed in capsule or tablet form, targeted to the pre-diabetic, Type-2 diabetic and digestive health, consumer market segments. There can be no assurance that we will be able to effectively compete in such a competitive environment.

Government Regulation

The manufacturing, processing, formulating, packaging, labeling, distributing, selling and advertising of our products are subject to government regulation, principally by the Food and Drug Administration (hereinafter the "FDA"). In particular, the FDA regulates the safety, manufacturing, labeling and distribution of dietary supplements. The FDA permits "statements of nutritional support" for dietary supplements without FDA pre-approval. Such statements may describe how particular dietary ingredients affect the structure, function or general well-being of the body, or the mechanism of action by which a dietary ingredient may affect body structure, function or well-being (but may not state that a dietary supplement will diagnose, mitigate, treat, cure or prevent a disease). A company making a statement of nutritional support must possess substantiating evidence for the statement, and, for such statements that are not about the effects on the body because of a dietary supplement used as a tool for its nutritive value and are not otherwise "health claims," disclose on the label that the FDA has not reviewed that statement and that the product is not intended for use for a disease. Failure to comply with applicable FDA requirements can result in various levels of regulatory actions being imposed on the Company including but not limited to action letters, product recalls and injunctions.

In addition to the FDA, the Federal Trade Commission (hereinafter the "FTC") has additional jurisdiction to regulate the labeling, promotion and advertising of dietary supplements. The FTC is authorized to use a variety of processes and remedies for enforcement, both administratively and judicially, including compulsory process, cease and desist orders, and injunctions. FTC enforcement can result in orders requiring, among other things, limits on advertising, corrective advertising, consumer redress, divestiture of assets, rescission of contracts and such other relief as may be deemed necessary. State and local authorities can also regulate advertising and labeling for dietary supplements and conventional foods. Additionally, there can be no assurance that state and local authorities will not commence other regulatory actions that could restrict the permissible scope of our product claims.

Item 10: The nature and extent of the issuer's facilities.

Our principal office is located at 609 SW 8th Street, Suite 600, Bentonville, AR 72712, which we rent monthly. We additionally contract for product manufacturing at facilities located in Gravette, Arkansas and Owatonna, Minnesota and logistics and fulfillment services at a facility in Rogers, Arkansas. We do not believe we will have difficulty in obtaining additional executive office, industrial manufacturing or commercial logistics space, at competitive prices, if necessary. We hold no real property.

Part D Management Structure and Financial Information

Item 11: The name of the chief executive officer, members of the board of directors, as well as control persons.

As of the date of this Annual Report, the following table sets forth information regarding our executive officers and director:

Name		Age		Position
Murray Fleming		56		Chief Executive Officer, Chief Financial Officer, Sole Director

On October 1, 2014, Murray Fleming was appointed our Chief Executive Officer. On February 10, 2015, Mr. Fleming was appointed our Chief Financial Officer. On February 4, 2016, Mr. Fleming, was appointed to our board of directors.

Our officers and director have not been convicted in a criminal proceeding or named as a defendant in a pending criminal proceeding; no entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction has permanently or temporarily enjoined, barred, suspended or otherwise limited our officers' or our director's involvement in any type of business, securities, commodities, or banking activities; no finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, limits our officers' or our director's involvement in any type of business or securities activities; and no entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended or otherwise limited our officers' or director's involvement in any type of business or securities activities, exists.

There are no family relationships between our officers and/or director.

Summary Compensation Table

The table set forth below summarizes the annual and long-term compensation for services in all capacities to us payable to our chief executive officer, our chief financial officer and our director for the fiscal years ended December 31, 2017 and 2016 and the quarterly period ended March 31, 2018.

Name and Principal Position	Period	Annual Compensation: Salary ($)	Annual Compensation: Bonus ($)	Annual Compensation: Other Annual Compensation ($)	Long Term Compensation Awards: Restricted Stock Awards ($)	Long Term Compensation Awards: Securities Underlying Options/SARs (#)	Long Term Compensation: Payouts LTIP Payouts ($)	All Other Compensation	Total Compensation
Murray Fleming	Q1 2018	None	None	None	None	None	None	None	None
CEO, CFO and director.	2017	None	None	None	None	None	None	None	None
	2016	None	None	None	None	None	None	None	None

Stock Options/SAR Grants

There are no arrangements for stock options or stock appreciation rights or similar benefits for our director or officers.

Long-Term Incentive Plans

There are no arrangements or plans in which we provide pension, retirement or similar benefits for our director or officers. We do not have any material bonus or profit sharing plans pursuant to which cash or non-cash compensation is or may be paid to our director or officers.

Director Compensation

Currently no compensation is paid to our director.

Related Party Transactions

Notes payable, related party:

On May 1, 2016, the Company issued a $35,000 note to a corporation owned by the Company's CEO. The loan bears interest at 24% per annum and has a maturity date of December 31, 2016. As of March 31, 2018, $20,000 remains outstanding.

On November 28, 2017, the Company issued a $25,000 note to a corporation owned by the Company's CEO. The loan bears interest at 12% per annum and has a maturity date of March 28, 2018. As of March 31, 2018, $25,000 remains outstanding.

On March 29, 2018, the Company issued a $20,000 note to a corporation owned by the Company's CEO. The loan bears interest at 12% per annum and has a maturity date of July 29, 2018. As of March 31, 2018, $20,000 remains outstanding.

Convertible notes payable, related party

The Company consolidated 18 separate convertible promissory notes of various principal amounts and fixed conversion prices, all bearing 5% interest per annum, issued to a corporation owned by the Company's CEO during the period from August 4, 2014 through April 1, 2016, into a single convertible promissory note of $112,157, bearing 5% interest per annum with a pro-rata fixed conversion price of $0.011, plus $5,939 accrued interest not subject to additional interest. The consolidation was for the purposes of administrative simplification and no inducement nor benefit was given to the corporation owned by the Company's CEO. As of March 31, 2018, the note balance is $112,157.

Item 12: Financial information for the issuer's most recent fiscal period.

GLUCOSE HEALTH INC.
INDEX TO FINANCIAL STATEMENTS

GLUCOSE HEALTH, INC.
BALANCE SHEETS
(unaudited)

ASSETS	March 31, 2018	December 31, 2017
CURRENT ASSETS		
Cash	$ 5,618	$ 22,406
Accounts receivable, net of allowance for doubtful accounts of $11,596 and $11,596, respectively	6,029	1,441
Inventory - raw materials	74,986	45,340
Total current assets	86,633	69,187
Other Asset		
Intellectual assets, net of accumulated amortization of $120 and $60, respectively	165	180
TOTAL ASSETS	$ 86,798	$ 69,367
LIABILITIES AND STOCKHOLDERS' DEFICIT		
CURRENT LIABILITIES		
Accounts payable and accrued expenses	$ 36,085	$ 36,585
Accrued interest	49,468	49,176
Notes payable, related party	65,000	60,000
Notes payable	60,000	35,000
Convertible notes payable, related party	112,157	112,157
Convertible notes payable	150,630	156,070
Other notes payable	10,500	10,500
Total current liabilities	483,840	459,488
TOTAL LIABILITIES	483,840	459,488
COMMITMENT AND CONTINGENCIES		
STOCKHOLDERS' DEFICIT		
Preferred stock, no par value, 1,000 shares authorized, 1,000 shares issued and outstanding as of December 31, 2017 and December 31, 2016	113,200	113,200
Common stock, $0.001 par value, 200,000,000 shares authorized, 4,971,895 and 3,312,273 shares issued and outstanding as of December 31, 2017 and December 31, 2016, respectively	5,716	4,972
Additional paid in capital	5,729,864	5,724,655
Stock subscription	23,000	23,000
Accumulated other comprehensive loss	(75,278)	(75,278)
Accumulated deficit	(6,193,545)	(6,180,670)
Total stockholders' deficit	(397,043)	(390,121)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 86,798	$ 69,367

The accompanying notes are an integral part of these financial statements.

GLUCOSE HEALTH INC.
STATEMENTS OF OPERATIONS
(unaudited)

	THREE MONTH'S ENDED MARCH 31,	
	2018	**2017**
REVENUE	$ 38,421	$ 15,111
COST OF REVENUES		
Cost of revenues	23,557	14,638
GROSS PROFIT	14,864	473
OPERATING EXPENSES		
Professional fees	13,651	16,296
General and administrative	9,324	12,490
Total Operating Expenses	22,975	28,786
LOSS FROM OPERATIONS	(8,111)	(28,313)
OTHER INCOME (EXPENSE)		
Interest income (expense)	(3,898)	(696)
Total other expense	(3,898)	(696)
LOSS BEFORE INCOME TAXES	(12,009)	(29,009)
PROVISION FOR (BENEFIT FROM) INCOME TAXES	-	-
NET LOSS	$ (12,009)	$ (29,009)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING BASIC AND DILUTED	5,292,209	3,341,930
NET LOSS PER SHARE - BASIC AND DILUTED	$ (0.00)	$ (0.01)

The accompanying notes are an integral part of these financial statements.

GLUCOSE HEALTH, INC.
STATEMENTS OF CASH FLOWS
(unaudited)

	FOR THE THREE MONTH'S ENDED MARCH 31, 2018	2017
OPERATING ACTIVITIES:		
Net loss	$ (12,009)	$ (29,009)
Adjustments to reconcile net loss to net cash used in operating activities:		
Amortization of intangible asset	15	15
Change in assets and liabilities		
(Increase) decrease in accounts receivable	(4,588)	2,092
Decrease (increase) in inventory	(29,646)	-
(Increase) decrease in prepaid expenses and other current assets	-	639
Increase (decrease) in accounts payable and accrued expenses	(560)	14,729
Total adjustments	(34,779)	17,475
Net cash used in operating activities	(46,788)	(11,534)
CASH FLOWS FROM INVESTING ACTIVITIES:		
Net cash used in investing activities	-	-
CASH FLOWS FROM FINANCING ACTIVITIES:		
Proceeds from notes and loans payable	45,000	-
Payments on notes and loans payable	(15,000)	
Net cash provided by financing activities	30,000	-
NET DECREASE IN CASH	(16,788)	(11,534)
CASH - BEGINNING OF YEAR	22,406	20,542
CASH - END OF YEAR	$ 5,618	$ 9,008
NONCASH OPERATING AND INVESTING ACTIVITIES:		
Conversion of notes payable and accrued interest to common stock	$ 5,954	$ 890

The accompanying notes are an integral part of these financial statements.

CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS

Some of the statements in this report are "forward-looking statements." These forward-looking statements involve certain known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. The words "believe," "expect," "anticipate," "intend," "plan," and similar expressions identify forward-looking statements. We caution you not to place undue reliance on these forward-looking statements. We undertake no obligation to update and revise any forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements in this report to reflect any future or developments. However, the Private Securities Litigation Reform Act of 1995 is not available to us as a penny stock issuer and thus we may not rely on the statutory safe harbor from liability for forward-looking statements. Further, Section 27A(b)(2)(D) of the Securities Act of 1933 and Section 21E(b)(2)(D) of the Securities Exchange Act of 1934 expressly state that the safe harbor for forward looking statements does not apply to statements made in connection with any offering.

EXPLANATORY NOTE

Unless otherwise indicated or the context otherwise requires, all references in this Quarterly Report to "we," "us," "our," and the "Company" are to Glucose Health, Inc., a Nevada corporation.

In this Quarterly Report, unless otherwise specified, all dollar amounts are expressed in United States dollars.

The Company's financial statements are stated in United States Dollars (US$) and are prepared in accordance with United States generally accepted accounting principles.

NOTE 1 – ORGANIZATION AND BASIS OF PRESENTATION

We were incorporated under the laws of State of Nevada on March 27, 2007, as Bio-Solutions Corp. On October 30, 2014, we changed our name to Glucose Health, Inc. to reflect our current business. Our authorized shares of Common Stock are 200,000,000 and our authorized shares of Series A Special Preferred Voting Shares are 1000. As of March 31, 2018, 5,716,133 shares of our Common Stock and 1,000 shares of our Series A Special Preferred Shares, were issued and outstanding. Our business is the manufacturing and sales of Glucose Health® branded dietary supplement products. For the fiscal quarter ending March 31, 2018, we generated a gross profit of $14,864, a loss from operations of $8,111 and net loss of $12,009 or $0.00 per share.

Basis of Presentation

The accompanying unaudited condensed interim financial statements have been prepared in accordance with generally accepted accounting principles in the United States for interim financial information. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements.

In the opinion of management, the financial statements contain all material adjustments, consisting only of normal recurring adjustments necessary to present fairly the financial condition, results of operations, and cash flows of the Company for the interim periods presented.

The results for the three months ended March 31, 2018 are not necessarily indicative of the results of operations for the full year. These financial statements and related footnotes should be read in conjunction with the consolidated financial statements and footnotes thereto included in the Company's Annual Report for the year ended December 31, 2017, available on OTCMarkets.com.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to revenue recognition, bad debts, investments, intangible assets, and income taxes. Our estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from these estimates.

Comprehensive Income (Loss)

The Company adopted ASC 220-10, "Reporting Comprehensive Income." ASC 220-10 requires the reporting of comprehensive income in addition to net income from operations. Comprehensive income is a more inclusive financial reporting methodology that includes disclosure of information that historically has not been recognized in the calculation of net income.

Cash Flow Reporting

The Company follows ASC 230, Statement of Cash Flows, for cash flow reporting, classifies cash receipts and payments according to whether they stem from operating, investing, or financing activities and provides definitions of each category, and uses the indirect or reconciliation method ("indirect method") as defined by ASC 230, Statement of Cash Flows, to report net cash flow from operating activities by adjusting net income to reconcile it to net cash flow from operating activities by removing the effects of (a) all deferrals of past operating cash receipts and payments and all accruals of expected future operating cash receipts and payments and (b) all items that are included in net income that do not affect operating cash receipts and payments.

Cash and Cash Equivalents

The Company considers all highly liquid debt instruments and other short-term investments with maturity of three months or less, when purchased, to be cash equivalents. There were no cash equivalents as of March 31, 2018 and 2017.

The Company maintains its cash balances at one financial institution that is insured by the Federal Deposit Insurance Corporation.

Accounts Receivable

Accounts receivable consists of invoiced and unpaid product sales. The Company records an allowance for doubtful accounts to allow for any amounts that may not be recoverable, which is based on an analysis of the Company's prior collection experience, customer credit worthiness, and current economic trends. During the quarters ended March 31, 2018 and 2017, we recorded no allowances for doubtful accounts based upon management's review of accounts receivable.

On October 4, 2016, the Company executed a non-recourse receivables financing agreement with Citibank whereby receivables due to the Company are assumed from a large customer by Citibank and paid to the Company in a shorter period than otherwise provided for in accordance with the supplier agreement with the large customer, subject to a fixed interest premium based upon LIBOR.

Prepaid Expenses

The Company considers all items incurred for future services to be prepaid expenses. As of March 31, 2018, the Company had no prepaid expenses.

Recoverability of Long-Lived Assets

The Company reviews its long-lived assets on a periodic basis, namely intellectual property, whenever events and changes in circumstances have occurred which may indicate a possible impairment. The assessment for potential impairment will be based primarily on the Company's ability to recover the carrying value of its long-lived assets from expected future cash flows from its operations on an undiscounted basis. If such assets are determined to be impaired, the impairment recognized is the amount by which the carrying value of the assets exceeds the fair value of the assets. Fixed assets to be disposed of by sale will be carried at the lower of the then current carrying value or fair value less estimated costs to sell.

The Company evaluates the carrying value of goodwill during the fourth quarter of each year and between annual evaluations if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount. Such circumstances could include, but are not limited to, (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. When evaluating whether goodwill is impaired, the Company compares the fair value of the reporting unit to which the goodwill is assigned to the reporting unit's carrying amount, including goodwill. The fair value of the reporting unit is estimated using a combination of the income, or discounted cash flows, approach and the market approach, which utilizes comparable companies' data. If the carrying amount of a reporting unit exceeds its fair value, then the amount of the impairment loss must be measured. The impairment loss would be calculated by comparing the implied fair value of reporting unit goodwill to its carrying amount. In calculating the implied fair value of reporting unit goodwill, the fair value of the reporting unit is allocated to all the other assets and liabilities of that unit based on their fair values. The excess of the fair value of a reporting unit over the amount assigned to its other assets and liabilities, is the implied fair value of goodwill.

We make critical assumptions and estimates in completing impairment assessments of goodwill and other intangible assets. Our cash flow projections look several years into the future and include assumptions on variables such as future sales and operating margin growth rates, economic conditions, market competition, inflation and discount rates. A 10% decrease in the estimated discounted cash flows for the reporting units tested would result in impairment that is not material to our results of operations. A 1.0 percentage point increase in the discount rate used would also result in impairment that is not material to our results of operations.

We amortize the cost of other intangible assets over their estimated useful lives, which range up to ten years, unless such lives are deemed indefinite. Intangible assets with indefinite lives are tested in the third quarter of each fiscal year for impairment, or more often if indicators warrant.

During the quarters ended March 31, 2018 and 2017, we recorded no impairment charges related to other intangible assets.

Fair Value of Financial Instruments

The carrying amount reported in the balance sheets for cash, accounts payable, accrued expenses, and short-term notes approximate fair value because of the immediate or short-term maturity of these financial instruments. The Company does not utilize derivative instruments.

ASC 820, *Fair Value Measurements and Disclosures*, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

Level 1 Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities

Level 2 Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

Level 3 Inputs that are both significant to the fair value measurement and unobservable.

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of March 31, 2018. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.

Beneficial Conversion Features

ASC 470-20 applies to convertible securities with beneficial conversion features that must be settled in stock and to those that give the issuer a choice in settling the obligation in either stock or cash. ASC 470-20 requires that the beneficial conversion feature should be valued at the commitment date as the difference between the conversion price and the fair market value of the Common Stock into which the security is convertible, multiplied by the number of shares into which the security is convertible. This amount is recorded as a debt discount and amortized over the life of the debt. ASC 470-20 further limits this amount to the proceeds allocated to the convertible instrument.

Income Taxes

The Company accounts for income taxes utilizing the liability method of accounting. Under the liability method, deferred taxes are determined based on differences between financial statement and tax bases of assets and liabilities at enacted tax rates in effect in years in which differences are expected to reverse. Valuation allowances are established, when necessary, to reduce deferred tax assets to amounts that are expected to be realized.

The Company follows ASC 740-10, "Accounting for Uncertainty in Income Taxes" ("ASC 740-10"). This interpretation requires recognition and measurement of uncertain income tax positions using a "more-likely-than-not" approach. The Company has adopted ASC 740-10 for 2016, and evaluates its tax positions on an annual basis, and as of December 31, 2017, no additional accrual for income taxes is necessary. The Company's policy is to recognize both interest and penalties related to unrecognized tax benefits expected to result in payment of cash within one year are classified as accrued liabilities, while those expected beyond one year are classified as other liabilities. The Company has not recorded any interest or penalties since its inception. The Company is required to file income tax returns in the U.S. federal tax jurisdiction and in various state tax jurisdictions and tax years 2014, 2015 and 2016 remain open for examination by federal and/or state tax jurisdictions. The Company is currently not under examination by any other tax jurisdictions for any tax year.

Revenue Recognition

In accordance with Securities and Exchange Commission Staff Accounting Bulletin (SAB) No. 104, *Revenue Recognition*, (codified in ASC 605) the Company recognizes revenue when (i) persuasive evidence of a customer or distributor arrangement exists or acceptance occurs, (ii) a retailer, distributor or wholesaler receives the goods, (iii) the price is fixed or determinable, and (iv) collectability of the sales revenues is reasonably assured.

Share Based Compensation

The Company accounts for share-based compensation in accordance with the fair value recognition provisions of the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") No. 718 and No. 505. The Company issues restricted stock to employees for their services. Cost for these transactions are measured at the fair value of the equity instruments issued at the date of grant. These shares are considered fully vested and the fair market value is recognized as expense in the period granted. The Company also issues restricted stock to consultants for various services. Costs for these transactions are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The value of the

Common Stock is measured at the earlier of (i) the date at which a firm commitment only if there is sufficient disincentive to ensure performance or (ii) the date at which the counterparty's performance is complete. The Company recognized consulting expenses and a corresponding increase to additional paid-in-capital related to stock issued for services. For agreements requiring future services, the consulting expense is to be recognized ratably over the requisite service period.

(Loss) Income Per Share of Common Stock

Basic net loss/income per common share is computed using the weighted average number of common shares outstanding. Diluted earnings per share (EPS) include additional dilution from Common Stock equivalents, such as stock issuable pursuant to the exercise of stock options warrants and convertible notes. Common Stock equivalents are not included in the computation of diluted earnings per share when the Company reports a loss because to do so would be anti-dilutive for periods presented. The Company has not issued any options or warrants. At March 31, 2018, the total shares of Common Stock issuable upon conversion of all our convertible notes payable to equity, would be approximately 32,804,695 shares. However, all our convertible notes payable include terms restricting conversions to equity, such that the holder may own a maximum of 4.99% of our issued and outstanding Common Stock, at any given time.

Inventory

Inventory is stated at the lower of cost (FIFO: first-in, first-out) or market, and includes finished goods and raw materials. The cost of finished goods includes the cost of packaging supplies, direct and indirect labor and other indirect manufacturing costs. As of March 31, 2018, the Company had raw materials inventory of $74,986, with no allowance for obsolescence.

Recently Issued Accounting Standards Not Yet Adopted

None.

NOTE 3 – STOCKHOLDERS' DEFICIT

Our authorized shares are 200,000,000 shares of Common Stock and 1000 Series A Special Preferred Voting Shares. As of March 31, 2018, 5,716,133 shares of our Common Stock and 1,000 shares of our Series A Preferred Voting Shares were issued and outstanding.

Issuances pursuant to conversions

During March 2017, the Company issued 111,214 unregistered shares of Common Stock to a corporation for conversion of $850 principal and $40 accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.

During April 2017, the Company issued 162,500 unregistered shares of Common Stock to a corporation for conversion of $1,300 of accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.

During May 2017, the Company issued 176,938 unregistered shares of Common Stock to a corporation for conversion of $600 principal and $816 accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.

During May 2017, the Company issued 6,127 unregistered shares of Common Stock to three corporations for a mandatory conversion of $19,222 principal and $689 accrued interest related to three individual notes. These unregistered shares were valued at $3.25 per share, the fixed conversion price stated in the note, as adjusted for the two stock splits that occurred between the mandatory conversion date and the issuance of the Common Stock.

During June 2017, the Company issued 6,127 unregistered shares of Common Stock to three corporations in conversion of $19,222 principal and $689 accrued interest outstanding, related to three notes issued June 11, 2013. These unregistered shares were valued at $3.25 per share, the fixed conversion price stated in the note, as adjusted for the two stock splits that occurred between the mandatory conversion date and the issuance of the Common Stock.

During June 2017, the Company issued 185,740 unregistered shares of Common Stock to a corporation for conversion of $1,400 principal and $86 accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.

During August 2017, the Company issued 187,500 unregistered shares of Common Stock to a corporation for conversion of $1,500 accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.

During August 2017, the Company issued 160,500 unregistered shares of Common Stock to a corporation for conversion of $1,200 principal and $84 accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.

During September 2017, the Company issued 188,018 unregistered shares of Common Stock to a corporation for conversion of $1,400 principal and $104 accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.

During October 2017, the Company issued 12,000 unregistered shares of Common Stock to an individual in conversion of a $6,000 outstanding balance related to a note issued January 25, 2013, in accordance with a contractual agreement and retired the note. These unregistered shares were valued at 0.1609 per share, however, the conversion price was $0.001, the fixed conversion price.

During November 2017, the Company issued 216,274 unregistered shares of Common Stock to a corporation for conversion of $1,600 principal and $130 accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.

During December 2017, the Company issued 210,311 unregistered shares of Common Stock to a corporation for conversion of $1,550 principal and $132 accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.

During January 2018, the Company issued 238,163 unregistered shares of Common Stock to a corporation for conversion of $1,750 principal and $155 accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.

During March 2018, the Company issued 246,563 unregistered shares of Common Stock to a corporation for conversion of $1,800 principal and $173 accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.

During March 2018, the Company issued 259,512 unregistered shares of Common Stock to a corporation for conversion of $1,890 principal and $186 accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.

Issuances pursuant to agreements

During October 2017, the Company issued 17,500 shares of unregistered Common Stock to an individual. The unregistered Common Stock was valued at $2,818.

NOTE 4 – NOTES PAYABLE

Notes payable, related party:

On May 1, 2016, the Company issued a $35,000 note to a corporation owned by the Company's CEO. The loan bears interest at 24% per annum and has a maturity date of December 31, 2016. As of March 31, 2018, $20,000 remains outstanding.

On November 28, 2017, the Company issued a $25,000 note to a corporation owned by the Company's CEO. The loan bears interest at 12% per annum and has a maturity date of March 28, 2018. As of March 31, 2018, $25,000 remains outstanding.

During March 2018, the Company issued a $20,000 note to a corporation owned by the Company's CEO. The loan bears interest at 12% per annum and has a maturity date of July 29, 2018. As of March 31, 2018, $20,000 remains outstanding.

Notes payable:

On May 15, 2017, the Company issued an $18,000 note to a corporation. The loan bears interest at 12% per annum and is payable on demand. As of March 31, 2018, $10,000 remains outstanding.

On November 22, 2017, the Company signed a $60,000 revolving line of credit agreement with a corporation. The outstanding balance bears simple interest of 10% per annum, payable monthly in arrears. As of March 31, 2018, $50,000 is outstanding.

Convertible notes payable, related party

The Company consolidated 18 separate convertible promissory notes of various principal amounts and fixed conversion prices, all bearing 5% interest per annum, issued to a corporation owned by the Company's CEO during the period from August 4, 2014 through April 1, 2016, into a single convertible promissory note of $112,157, bearing 5% interest per annum with a pro-rata fixed conversion price of $0.011, plus $5,939 accrued interest not subject to additional interest. The consolidation was for the purposes of administrative simplification and no inducement nor benefit was given to the corporation owned by the Company's CEO. As of March 31, 2018, the note balance is $112,157.

Convertible notes payable:

The Company consolidated 20 separate convertible promissory notes of various principal amounts and fixed conversion prices, all bearing 5% interest per annum, issued to corporation during the period from August 2, 2013 through April 1, 2016, into a single convertible promissory note of $169,065, bearing 5% interest per annum with a pro-rata fixed conversion price of $0.008, plus $12,516 accrued interest not subject to additional interest. The consolidation was for the purposes of administrative simplification and no inducement nor benefit was given to the corporation. As of March 31, 2018, the note balance is $150,630.

Other notes payable:

On December 10, 2013, the Company issued a $3,000 convertible note to an individual. The loan bears interest at 5% per annum, has a fixed conversion price of $0.015 and a maturity date of June 10, 2014. As of March 31, 2018, $3,000 remains outstanding.

On December 10, 2013, the Company issued a $5,000 convertible note to an individual. The loan bears interest at 5% per annum, has a fixed conversion price of $0.015 and a maturity date of June 10, 2014. As of March 31, 2018, $5,000 remains outstanding.

On April 20, 2012, the Company issued a $2,500 convertible note to an individual. The loan bears interest at 5% per annum, has a fixed conversion price of $0.009 and a maturity date of October 20, 2012. As of March 31, 2018, $2,500 remains outstanding.

Accrued Interest

At March 31, 2018, accrued interest on all notes and convertible notes amounted to $49,468.

NOTE 5 – INTELLECTUAL PROPERTY

On October 1, 2014, the Company entered into an Intellectual Property Purchase Agreement to purchase "Glucose Health" for the purchase price of 300,000 unregistered shares of the Company's Common Stock from a company beneficially owned by the Company's CEO, Murray Fleming. The shares were recorded at their par value of $0.001 per share or $300, valued at the nominal historical cost of the related party seller. All assets other than the intellectual property had a fair value of $0, with the intellectual property valued at $165 net of $265 of accumulated amortization.

NOTE 6 – COMMITMENTS/CONTINGENCIES

From time to time, we may be involved in litigation in the ordinary course of business. We are currently not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations.

Operating Agreements

On January 8, 2016, we entered into a supplier agreement with a national retailer customer.

On January 25, 2016, we entered into an agreement for manufacturing services with Natural Solution Labs of Gravette, AR.

On April 12, 2016, we entered into an agreement for warehousing, logistics and fulfillment services NWA Logistics of Rogers, AR.

On February 5, 2017, we entered into a Commercial General Liability insurance policy underwritten by Lloyd's of London represented by Citadel Insurance Services.

On November 27, 2017 we entered into an agreement for manufacturing services with Zumbro River Brands of Albert Lea, MN.

NOTE 7 – MAJOR CUSTOMERS and ACCOUNTS RECEIVABLE

The Company has a one customer whose revenue individually represents more than 10% of the Company's total revenues and one customer whose accounts receivable represents more than 10% of the Company's accounts receivable. The Company expects to maintain this relationship and has assessed the credit worthiness of this customer and does not currently believe an allowance for accounts receivable impairment is required.

NOTE 8 – SUBSEQUENT EVENTS

None.

Item 13: Similar financial information for such part of the two preceding fiscal years as the issuer or its predecessor has been in existence.

The issuer's fiscal 2017 Annual Report posted to OTCMarkets.com on May 15, 2018, which includes Balance Sheets, Statements of Operations, Statement of Changes in Stockholders' Deficit, Statements of Cash Flows and Notes to the Financial Statements for the periods ending December 31, 2017 and 2016, is hereby incorporated by reference.

The issuer's fiscal 2016 Annual Report posted to OTCMarkets.com on May 15, 2018, which includes Balance Sheets, Statements of Operations, Statement of Changes in Stockholders' Deficit, Statements of Cash Flows and Notes to the Financial Statements for the periods ending December 31, 2016 and 2015, is hereby incorporated by reference.

Item 14: Beneficial Owners.

The following table sets forth certain information regarding the beneficial ownership of our Common Stock as of March 31, 2018, by each person or entity known by us to be the beneficial owner of more than 5% of the outstanding shares of Common Stock, our director(s) and named executive officer(s), and all of our director(s) and executive officer(s) as a group.

Title of Class	Name of Beneficial Owner	Amount and Nature of Beneficial Owner	Percent of Class
	Officers and Directors		
Common Stock	Murray Fleming, CEO, CFO, director.	600,000 shares	10%*
Common Stock	All director(s) and named executive officer(s) as a group.	600,000 shares	10%*
Common Stock	5% and greater beneficial owners.	None	None

*Figures may vary due to rounding.

Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission and generally includes voting or investment power with respect to securities. In accordance with Securities and Exchange Commission rules, shares of our Common Stock which may be acquired upon exercise of stock options or warrants which are currently exercisable or which become exercisable within 60 days of the date of the table are deemed beneficially owned by the optionees. Subject to community property laws, where applicable, the persons or entities named in the table above have sole voting and investment power with respect to all shares of our Common Stock indicated as beneficially owned by them.

Item 15: The name, address, telephone number, and email address of each of the following outside providers that advise the issuer on matters relating to operations, business development and disclosure:

1. Investment Banker: None

2. Promoters None

3. Disclosure Counsel: The McGeary Law Firm, PC
   1600 Airport Freeway
   Suite 300 Bedford, TX 76022
   Tel: (914) 220-1900

4.	Accountant/Auditor*:	Norco Accounting and Consulting, Inc. 15837 Trackside Drive Odessa, FL 33556 www.norcoconsulting.com
5.	Public Relations Consultant:	None
6.	Corporate Secretary:	Murray Fleming
7.	Any other advisor:	None

*Preparation of Glucose Health, Inc.'s consolidated financial statements are the responsibility of Glucose Health, Inc. officers/director. Norco Accounting and Consulting, Inc. has prepared the consolidated financial statements. Norco Accounting and Consulting, Inc. has confirmed to us that the firm is licensed to practice public accounting.

Item 16: Management's Discussion and Analysis or Plan of Operation.

Overview

Glucose Health, Inc. manufacturers and distributes dietary supplements under the Glucose Health® brand. As discussed in greater detail below, we are in the early stages of developing, manufacturing, marketing and distributing our products. For the fiscal quarter ending March 31, 2018, we generated a gross profit of $14,864, a loss from operations of $8,111 and net loss of $12,009 or $0.00 per share.

Glucose Health, Inc. dietary supplement products are formulated with ingredients demonstrated in certain clinical research, such as published on the National Institutes of Health, National Library of Medicine website (see www.glucosehealth.com/clinical-trials), to have a beneficial impact upon blood glucose, triglyceride and cholesterol levels and digestive health. The Centers for Disease Control and Prevention (CDC) publishes a National Diabetes Statistics Report annually. The 2014 Report estimates 2 of 5 presently healthy Americans will develop Type-2 diabetes in their lifetime. We believe the CDC Report and other similar research points to a large and growing market of consumers likely concerned with pre-diabetes or Type-2 diabetes, including many of whom are also likely purchasers of dietary supplements. While our primary focus is growing our sales to these consumers through national and regional pharmacy chain retailers, secondarily, we also market Glucose Health® to these customers via selected online marketplaces.

Recent Developments

On January 6, 2016, we executed a supplier agreement with a large national pharmacy retailer.

On February 4, 2016, our Chief Executive Officer and Chief Financial Officer, Murray Fleming, was appointed to our board of directors.

On March 8, 2016, we received a series of material purchase orders from a large national pharmacy retailer pursuant to a material supplier agreement.

On October 4, 2016, we executed a non-recourse receivables financing agreement with Citibank, N.A. (Citibank) whereby receivables are paid to us by Citibank for a large pharmacy retailer customer, subject to an interest premium.

In April 2017, we undertook a series of steps to achieve production of a new and improved, second iteration, Glucose Health® dietary supplement product. This series of steps included improving the nutritional formula with the addition of 6 targeted vitamins and minerals and the natural plant extract Banaba Leaf; implementation of an additional manufacturing process to agglomerate the product formula to improve solubility; sourcing natural flavors from an industry leading flavoring house; and improving product directions and packaging information based upon consumer feedback from the first iteration product.

In February 2018, we introduced new Glucose Health® Diabetic-Friendly Iced Tea Mix in Mixed Berry, Triple Berry, Lemon and Peach flavors. We are engaged in active development of additional products targeting our market niche.

As of March 31, 2018, Glucose Health® dietary supplements are stocked by pharmacy chain retailers in all 50 states and are additionally available for purchase in selected online marketplaces.

Our Plan of Operation for the Next Twelve Months

Our principal business strategy for the next twelve months will be to implement marketing and sales initiatives and earn significant revenues from the manufacture and distribution of our Glucose Health® dietary supplement products. Our sales initiatives will be focused upon securing repeat purchase orders for Glucose Health® products from national and regional pharmacy chain retailers. Our marketing initiatives will be primarily focused on supporting Glucose Health® sales through national and regional pharmacy chain retailers. We intend to continue advertising in and sponsoring, various print, digital and social media platforms, which align with the interest of our customers in dietary supplements related to pre-diabetes, Type-2 diabetes and digestive health. Secondarily to our primary sales and marketing initiatives above, we also intend to grow our online sales of Glucose Health® products through sales generated from online retailers; in particular, from diabetic-supplies focused online retailers. We also intend to further develop our Glucose Health® brand; introducing line extensions such as new flavor variations and additional packaging and sizing options.

Use of Estimates

The discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to revenue recognition, bad debts, investments, intangible assets, and income taxes. Our estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from these estimates.

Results of Operations

The following discussion should be read in conjunction with our financial statements.

Results of Operations for the Quarter Ended March 31, 2018 Compared to Quarter Ended March 31, 2017

Revenues

We generated revenues of $38,421 and $15,111 for the quarters ended March 31, 2018 and 2017, respectively. The principal reason for the increase in our revenues is due to more purchase orders being received from our largest customer for replenishment of their retail outlets in the quarter ended March 31, 2018, compared to the period ending March 31, 2017. We intend to more fully implement our plan of operations by December 31, 2018 and generate greater revenues from more customers, of which there is no assurance.

Gross profit

We reported a gross profit of $14,864 and $473 for the quarters ended March 31, 2018 and 2017, respectively. The principal reason for the increase in gross profit is due to more costs of raw materials and manufacturing for production of our inventory being incurred in the quarter ended March 31, 2017, compared to March 31, 2018. We intend to fully implement our plan of operations by December 31, 2018 and generate greater gross profits by achieving reductions in our raw materials and manufacturing costs, of which there is no assurance, and to retain and invest such profits in expanding and improving the efficiency of our operations, of which there is no assurance.

Operating expenses

For the quarter ended March 31, 2018, we had total operating expenses of $22,975, as compared to total operating expenses of $28,786 for the quarter ended March 31, 2017. The decrease of $5,811 in our operating expenses between the two periods is due to our ongoing efforts to reduce general and administrative expenses by limiting employees and contractors and their remuneration. We will continue to incur significant legal and accounting expenses related to maintaining our status as a publicly-traded company.

Net income/loss

For the quarter ended March 31, 2018, we had a net loss of $12,009 or $0.00 per share. In comparison, for the quarter ended March 31, 2017, we had a net loss of $29,009 or $0.02 per share. The decrease of $17,000 in our net loss between the two periods, is due to our ongoing efforts to reduce general and administrative expenses by limiting employees and contractors and their remuneration.

Results of Operations for the Year Ended December 31, 2017 Compared to Year Ended December 31, 2016

Revenues

We generated revenues of $104,522 and $313,229 for the years ended December 31, 2017 and 2016, respectively. The principal reason for the decline in our revenues is due to more purchase orders being received from our largest customer for initial stocking of their retail outlets in the year ended December 31, 2016, compared to purchase orders for the ongoing replenishment of their retail outlets in the period ending December 31, 2017. We intend to more fully implement our plan of operations by December 31, 2018 and generate greater revenues from more customers, of which there is no assurance.

Gross profit

We reported a gross profit of $87,548 and $19,167 for the years ended December 31, 2017 and 2016, respectively. The principal reason for the increase in gross profit is due to more costs of raw materials and manufacturing for production of our inventory being incurred in the year ended December 31, 2016, compared to December 31, 2017. We intend to fully implement our plan of operations by December 31, 2018 and generate greater gross profits by achieving reductions in our raw materials and manufacturing costs, of which there is no assurance, and to retain and invest such profits in expanding and improving the efficiency of our operations, of which there is no assurance.

Operating expenses

For the year ended December 31, 2017, we had total operating expenses of $93,357, as compared to total operating expenses of $105,814 for the year ended December 31, 2016. The decrease of $12,457 or 12%, in our operating expenses between the two periods is due to our ongoing efforts to reduce general and administrative expenses by limiting employees and contractors and their remuneration. We will continue to incur significant legal and accounting expenses related to maintaining our status as a publicly-traded company.

Net income/loss

For the year ended December 31, 2017, we had net income of $80,023 or $0.02 per share. In comparison, for the year ended December 31, 2016, we had a net loss of $410,443 or $0.15 per share. $323,796 of this net loss for the period ending December 31, 2016 related to the recording of interest expense and amortization of debt discount, a non-cash adjustment to reconcile net loss to net cash used in operations. We achieved greater net income in the December 31, 2017 period because we utilized less equity-based debt to finance our operations than in the period ended December 31, 2016. We also settled more accounts payable items in the period ended December 31, 2017, than the prior period, which resulted in the recording of gains and greater net income.

Liquidity and Capital Resources

At March 31, 2018, our current liabilities totaled $483,840, consisting of $36,085 in accounts payable and accrued expenses, $49,468 in accrued interest, $45,000 in notes payable, related party, $76,310 in notes payable, $112,157 in convertible notes payable, related party and $154,320 in convertible notes payable.

We had a working capital deficit for the period ended March 31, 2018 of $397,207. We continue to rely upon funding from two private firms, one which is beneficially owned by the Company's CEO, to meet our working capital requirements and continue our operations. Unless we continue secure additional funding from these firms, or others, of which there can be no assurance, we may not be able to continue our operations.

At March 31, 2018 and 2017, we had no other liabilities and no long-term commitments or contingencies.

At December 31, 2017, our total assets were $80,963, consisting of $22,406 cash, $45,340 inventory and $13,037 accounts receivable. This compares to our total assets of $33,145 at December 31, 2016, consisting of $20,542 cash, $0 inventory, $11,724 accounts receivable and $639 prepaid consultant compensation.

At December 31, 2017, our current liabilities totaled $458,028, consisting of $36,585 in accounts payable and accrued expenses, $47,716 in accrued interest, $60,000 in notes payable, related party, $35,000 in notes payable, $112,157 in convertible notes payable, related party, $166,570 in convertible notes payable. This compares to our current liabilities at December 31, 2016 of $528,592, consisting of $138,134 in accounts payable and accrued expenses, $38,631 in accrued interest, $35,000 in notes payable, related party, $5,000 in notes payable, $112,157 in convertible notes payable, related party, $164,793 in convertible notes payable and $35,000 in other notes payable.

We had a working capital deficit for period ended December 31, 2017 and 2016, of $377,245 and $495,687, respectively. We continue to rely upon funding from two private firms, one which is beneficially owned by the Company's CEO, to meet our working capital requirements and continue our operations. Unless we continue secure additional funding from these firms, or others, of which there can be no assurance, we may not be able to continue our operations.

At December 31, 2017 and 2016, we had no other liabilities and no long-term commitments or contingencies.

Material Commitments

Notes payable, related party:

On May 1, 2016, the Company issued a $35,000 note to a corporation owned by the Company's CEO. The loan bears interest at 24% per annum and has a maturity date of December 31, 2016. As of March 31, 2018, $20,000 remains outstanding.

On November 28, 2017, the Company issued a $25,000 note to a corporation owned by the Company's CEO. The loan bears interest at 12% per annum and has a maturity date of March 28, 2018. As of March 31, 2018, $25,000 remains outstanding.

During March 2018, the Company issued a $20,000 note to a corporation owned by the Company's CEO. The loan bears interest at 12% per annum and has a maturity date of July 29, 2018. As of March 31, 2018, $20,000 remains outstanding.

Notes payable:

On May 15, 2017, the Company issued an $18,000 note to a corporation. The loan bears interest at 12% per annum and is payable on demand. As of March 31, 2018, $10,000 remains outstanding.

On November 22, 2017, the Company signed a $60,000 revolving line of credit agreement with a corporation. The outstanding balance bears simple interest of 10% per annum, payable monthly in arrears. As of March 31, 2018, $50,000 is outstanding.

Convertible notes payable, related party

The Company consolidated 18 separate convertible promissory notes of various principal amounts and fixed conversion prices, all bearing 5% interest per annum, issued to a corporation owned by the Company's CEO during the period from August 4, 2014 through April 1, 2016, into a single convertible promissory note of $112,157, bearing 5% interest per annum with a pro-rata fixed conversion price of $0.011, plus $5,939 accrued interest not subject to additional interest. The consolidation was for the purposes of administrative simplification and no inducement nor benefit was given to the corporation owned by the Company's CEO. As of March 31, 2018, the note balance is $112,157.

Convertible notes payable:

The Company consolidated 20 separate convertible promissory notes of various principal amounts and fixed conversion prices, all bearing 5% interest per annum, issued to corporation during the period from August 2, 2013 through April 1, 2016, into a single convertible promissory note of $169,065, bearing 5% interest per annum with a pro-rata fixed conversion price of $0.008, plus $12,516 accrued interest not subject to additional interest. The consolidation was for the purposes of administrative simplification and no inducement nor benefit was given to the corporation. As of March 31, 2018, the note balance is $150,630.

Other notes payable:

On December 10, 2013, the Company issued a $3,000 convertible note to an individual. The loan bears interest at 5% per annum, has a fixed conversion price of $0.015 and a maturity date of June 10, 2014. As of March 31, 2018, $3,000 remains outstanding.

On December 10, 2013, the Company issued a $5,000 convertible note to an individual. The loan bears interest at 5% per annum, has a fixed conversion price of $0.015 and a maturity date of June 10, 2014. As of March 31, 2018, $5,000 remains outstanding.

On April 20, 2012, the Company issued a $2,500 convertible note to an individual. The loan bears interest at 5% per annum, has a fixed conversion price of $0.009 and a maturity date of October 20, 2012. As of March 31, 2018, $2,500 remains outstanding.

Accrued Interest

At March 31, 2018, accrued interest on all notes and convertible notes amounted to $49,468.

Off-Balance Sheet Arrangements

We have no-off balance sheet contractual arrangements.

Part E Issuance History

Item 17: List of securities offerings and shares issued for services in the past two years.

During the fiscal quarter ended March 31, 2018, we issued a total of 744,238 shares of Common Stock.

a) During January 2018, the Company issued 238,163 unregistered shares of Common Stock to a corporation for conversion of $1,750 principal and $155 accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.
b) During March 2018, the Company issued 246,563 unregistered shares of Common Stock to a corporation for conversion of $1,800 principal and $173 accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.
c) During March 2018, the Company issued 259,512 unregistered shares of Common Stock to a corporation for conversion of $1,890 principal and $186 accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.

During the fiscal year ended December 31, 2017, we issued a total of 1,659,622 shares of Common Stock.

a) During March 2017, the Company issued 111,214 unregistered shares of Common Stock to a corporation for conversion of $850 principal and $40 accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.
b) During April 2017, the Company issued 162,500 unregistered shares of Common Stock to a corporation for conversion of $1,300 of accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.
c) During May 2017, the Company issued 176,938 unregistered shares of Common Stock to a corporation for conversion of $600 principal and $816 accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.
d) During May 2017, the Company issued 6,127 unregistered shares of Common Stock to three corporations for a mandatory conversion of $19,222 principal and $689 accrued interest related to three individual notes. These unregistered shares were valued at $3.25 per share, the fixed conversion price stated in the note, as adjusted for the two stock splits that occurred between the mandatory conversion date and the issuance of the Common Stock.
e) During June 2017, the Company issued 185,740 unregistered shares of Common Stock to a corporation for conversion of $1,400 principal and $86 accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.
f) During August 2017, the Company issued 187,500 unregistered shares of Common Stock to a corporation for conversion of $1,500 accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.
g) During August 2017, the Company issued 160,500 unregistered shares of Common Stock to a corporation for conversion of $1,200 principal and $84 accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.
h) During September 2017, the Company issued 188,018 unregistered shares of Common Stock to a corporation for conversion of $1,400 principal and $104 accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.
i) During October 2017, the Company issued 17,500 unregistered shares of the Company's Common Stock to an individual. The shares were valued at $2,818.

j) During October 2017, the Company issued 12,000 unregistered shares of the Company's Common Stock to an individual for conversion of $6,000 principal note balance. These unregistered shares were valued at 0.1609 per share, however, the conversion price was valued at $0.01, the fixed conversion price. This resulted in a gain of $4,069.
k) During November 2017, the Company issued 216,274 unregistered shares of Common Stock to a corporation for conversion of $1,600 principal and $130 of accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.
l) During December 2017, the Company issued 210,311 unregistered shares of Common Stock to a corporation for conversion of $1,550 principal and $132 of accrued interest related to a note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the note.

During the fiscal year ended December 31, 2016, we issued a total of 860,385 shares of Common Stock.

a) During February 2016, the Company issued 90,094 shares of Common Stock to a corporation for conversion of $400 principal and $51 accrued interest pursuant to a note. These shares were valued at $0.005 per share.
b) During June 2016, the Company issued 130,000 shares of Common Stock to a corporation for conversion of $845 of accrued interest pursuant to a note. These shares were valued at $0.0065 per share.
c) During June 2016, the Company issued 81,250 shares of Common Stock to a corporation for conversion of $650 of accrued interest pursuant to a note. These shares were valued at $0.008 per share.
d) During July 2016, the Company issued 25,000 unregistered shares of the Company's Common Stock to an individual as compensation. The shares were valued at $1,875.
e) During August 2016, the Company issued 129,358 shares of Common Stock to a corporation for conversion of $1,000 principal and $35 accrued interest pursuant to a note. These shares were valued at $0.008 per share.
f) During September 2016, the Company issued 121,483 shares of Common Stock to a corporation for conversion of $950 principal and $22 accrued interest pursuant to a note. These shares were valued at $0.008 per share.
g) During October 2016, the Company issued 134,881 shares of Common Stock to a corporation for conversion of $1,050 principal and $29 accrued interest pursuant to a note. These shares were valued at $0.008 per share.
h) During November 2016, the Company issued 148,319 shares of Common Stock to a corporation for conversion of $1,150 principal and $37 accrued interest pursuant to a note. These shares were valued at $0.008 per share.

All issuances referenced above were exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933 (the "Securities Act"). The shares of Common Stock were not registered under the Securities Act or under any state securities laws and may not be offered or sold without registration with the United States Securities and Exchange Commission or alternatively, an applicable exemption from such registration requirements. The investors acknowledged that the securities had not been registered under the Securities Act; they understood the economic risk of an investment in the securities; and they had the opportunity to ask questions of and receive answers from our management concerning all matters related to acquisition of the securities. The sales were made to sophisticated or accredited investors, as defined in Rule 501(a). Further, we gave the purchasers the opportunity to ask questions and receive answers concerning the terms and conditions and to obtain any additional information which we possessed or could acquire without unreasonable effort or expense necessary to verify the accuracy of information furnished. At a reasonable time prior to the sale of securities, we advised the purchasers of the limitations on resale in the manner contained in Rule 502(d) 2. Neither we, nor any person acting on our behalf, sold the securities by any form of general solicitation or general advertising.

Recent Sales of Registered Securities

None.

Use of Proceeds of Registered Securities

Not applicable.

Penny Stock Regulation

Shares of our Common Stock are subject to rules adopted the Securities and Exchange Commission that regulate broker-dealer practices in connection with transactions in “penny stocks”. Penny stocks are generally equity securities with a price of less than $5.00 (other than securities registered on certain national securities exchanges or quoted on the NASDAQ system, provided that current price and volume information with respect to transactions in those securities is provided by the exchange or system). These penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from these rules to deliver a standardized risk disclosure document prepared by the Securities and Exchange Commission, which contains the following:

- a description of the nature and level of risk in the market for penny stocks in both public offerings and secondary trading;
- a description of the broker’s or dealer’s duties to the customer and of the rights and remedies available to the customer with respect to violation to such duties or other requirements of securities’ laws;
- a brief, clear, narrative description of a dealer market, including "bid" and "ask” prices for penny stocks and the significance of the spread between the "bid" and "ask" price;
- a toll-free telephone number for inquiries on disciplinary actions;
- definitions of significant terms in the disclosure document or in the conduct of trading in penny stocks; and
- such other information and is in such form (including language, type, size and format), as the Securities and Exchange Commission shall require by rule or regulation.

Prior to effecting any transaction in penny stock, the broker-dealer also must provide the customer the following:

- the bid and offer quotations for the penny stock;
- the compensation of the broker-dealer and its salesperson in the transaction;
- the number of shares to which such bid and ask prices apply, or other comparable information relating to the depth and liquidity of the market for such stock; and
- monthly account statements showing the market value of each penny stock held in the customer’s account.

In addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from these rules, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s written acknowledgment of the receipt of a risk disclosure statement, a written agreement to transactions involving penny stocks, and a signed and dated copy of a written suitability statement. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for a stock that becomes subject to the penny stock rules. Holders of shares of our Common Stock may have difficulty selling those shares because our Common Stock is subject to penny stock rules.

Part F Exhibits

Item 18: Material Contracts

The issuer hereby incorporates by reference Form 8-K filed with the Securities and Exchange Commission, March 11, 2016.

Item 19: Articles of Incorporation

The issuer hereby incorporates by reference Articles of Incorporation filed with the Securities and Exchange Commission as Exhibit 3.1 to Form SB-2, December 7, 2007.

Item 20: Purchases of Equity Securities by the Issuer and Affiliated Purchasers.

We did not repurchase any shares of our Common Stock in the quarterly period ended March 31, 2018 and in the fiscal years ended December 31, 2017 and 2016.

Item 21: Issuer's Certifications.

EXHIBIT 2.1

CERTIFICATION OF PRINCIPAL EXECUTIVE

I, Murray Fleming, Chief Executive Officer of Glucose Health, Inc., certify that:

1. I have reviewed this Initial Disclosure Statement of Glucose Health, Inc.;

2. Based on my knowledge, this Initial Disclosure Statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Initial Disclosure Statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this Initial Disclosure Statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this Initial Disclosure Statement.

/s/ Murray Fleming
Murray Fleming, Chief Executive Officer

Dated: May 15, 2018

EXHIBIT 2.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

I, Murray Fleming, Chief Financial Officer of Glucose Health, Inc., certify that:

1. I have reviewed this Initial Disclosure Statement of Glucose Health, Inc.;

2. Based on my knowledge, this Initial Disclosure Statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Initial Disclosure Statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this Initial Disclosure Statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this Initial Disclosure Statement.

/s/ Murray Fleming
Murray Fleming, Chief Financial Officer

Dated: May 15, 2018